Stanelco PLC
14 January 2008
14 January 2008
Stanelco plc ('Stanelco' or 'the Company')
Pre Close Update
Further to the Trading Statement of 29 May 2007 and the Interim Statement of 10
September 2007, the Board announces that the Company is expected to report a
loss in line with market expectations.
Sales growth has lagged forecast but this has been offset by the continued focus
on careful cost and cash management, which has resulted in a cash position that
is ahead of previous expectations.
The Company's cash balance at the 2007 year-end close was £8.0m, which will
provide greater resource for the commercialisation of the Company's technology.
Stanelco BioPlastics
The Board has strengthened this unit with the appointment in October 2007 of
Paul Law as Managing Director. Paul has a research and development background
in natural polymer chemistry and more recently a track record in the
commercialisation of innovative polymer products. He is already increasing the
commercial focus as we look to build revenues in this area of our business.
Whilst there continues to be considerable interest from potential customers,
some obstacles remain in commercialising bioplastics as reported previously. To
help meet the requirements of this developing market, the Company is installing
pilot extrusion and testing facilities at its UK base in Southampton during Q1
2008.
Biotec
Growth in the Biotec subsidiary has continued but at a slower rate than
anticipated. Satisfactory progress is being made towards assuaging the
previously reported patent challenges.
Stanelco RF Applications
The RF business continues to trade in line with expectations. We have increased
our contact with our existing customer base and this has resulted in a growing
number of customer enquiries particularly in the fibre optic furnace areas.
A detailed business update will be provided at the Preliminary Results on the
14th March 2008.
- Ends -
For further information please contact:
Jonathon Brill / Caroline Stewart
Financial Dynamics
Tel: +44 (0)20 7831 3113
This information is provided by RNS
The company news service from the London Stock Exchange MG
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.